ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) was the target of unusually large options trading on Friday. Investors acquired 9,749 call options on the company. This represents an increase of 125% compared to the typical daily volume of 4,330 call options.
Analyst Upgrades and Downgrades
IBRX has been the subject of a number of analyst reports. Piper Sandler reduced their price objective on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday.
View Our Latest Analysis on IBRX
Institutional Investors Weigh In On ImmunityBio
ImmunityBio Trading Up 26.4 %
Shares of NASDAQ:IBRX opened at $5.32 on Friday. The firm’s 50 day moving average is $3.72 and its two-hundred day moving average is $5.34. The firm has a market capitalization of $3.68 billion, a P/E ratio of -4.88 and a beta of 1.02. ImmunityBio has a 52 week low of $1.62 and a 52 week high of $10.53.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.53 million. Analysts predict that ImmunityBio will post -0.86 EPS for the current year.
ImmunityBio Company Profile
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
- Five stocks we like better than ImmunityBio
- What Investors Need to Know to Beat the Market
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Choose Top Rated Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are Growth Stocks and Investing in Them
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.